The biotechnology sector witnessed a striking demonstration of expedited drug development this week, with Boehringer Ingelheim receiving FDA approval for an innovative lung cancer therapy in less than two months,…
As reported in PR NewsWire; a pivotal Phase II/III trial to create a therapy for activated PI3K delta syndrome (APDS) has announced they’ve successfully completed patient enrollment for a new…
As recently reported in CheckOrphan, a new drug for sickle cell disease has quickly ascended through the FDA approval processes in an accelerated review. A New Sickle Cell Drug Shroud…
In an $8.7 billion agreement, Swiss drugmaker Novartis recently acquired AveXis. The company moved in such a way in order to acquire a developmental therapy for spinal muscular atrophy. The…
Little Emily Whitehead is looking attentively at a butterfly that has landed on her finger. She coos at it and lets it rest on the tip of her thumb peacefully.…
An exciting new development came out of presentations at the European Society of Cardiology conference in Spain this past weekend. We often hear about how previously approved FDA drugs for more…
Yowzaaa! You don’t want to miss the article by Jeannette Y. Wicks, RPh, MBA, FASCP about Cushing’s disease (CD). Cushing's is a rare disease that’s caused by high levels of…
Basel, Switzerland, June 10, 2015 – Results from pharmaceutical giant, Novartis’ new one-year clinical trial called MEASURE 2 pivotal Phase lll were announced today. The randomized, double-blind, trial studied for…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
